Replies to post #183493 on Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

Kevtrin is P2a and so is B-UPS

https://clinicaltrials.gov/ct2/show/NCT03042702

As to PofC trials not meeting ur standard -- see below // repost ... a must-read imo.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131484972

Science ultimately will determine all.
That's why Big Pharma is largely exiting R&D and buying out those smaller (smarter) risk takers with the 1 in 5000 lightbulb idea that works. Compound not as concepts but closer to market realities.

Just look to Juno and Kite with all their impressive suits and suites. I'll take the work being done in Beverly over most.

[F1ash]

"Kevetrin is a 1b trial, no? "

No

"Phase 2"

https://clinicaltrials.gov/ct2/show/NCT03042702?term=Kevetrin&rank=2

[alwaysdreaming]

Along with Mako shit pieces and attacks on a company in order to destroy it. Seems there is no holiday when it comes to destruction.

To find a company with perfect trials management, money situations, and products Good Luck. There will always be something to screw with to try and destroy someone or something. With Prurisol results coming can we find a chink in that trial as well, I bet we can if we dig hard enough.

Don't burn yourself when you light the Barbie 2moro celebrating honest and honorable human beings that sacrificed their lives doing what they believed in. Posting doubt in chat rooms trying to destroy a company is much more honorable to others.

[Jhawker]

Lol! Are you serious?

[MinnieM]

$CTIX - Both the Kevetrin Ovarian Cancer trial and the Brilacidin UP trial are ph 2's.

From the most recent 10-Q: https://www.sec.gov/Archives/edgar/data/1355250/000147793217002123/ctix_10q.htm

Cellceutix has commenced a Phase 2a trial of Kevetrin in treating late-stage ovarian cancer. The main objective of the trial focuses on confirming the modulation by Kevetrin of p53 pathways in tumors, as well as monitoring the response of tumors to the treatment. Presently and concurrent with the Phase 2a trial is the development of an oral formulation of Kevetrin for treating cancer. Pharmacokinetic data collected on Kevetrin during the initial clinical trial demonstrates that the compound has a short half-life of approximately two hours. Kevetrin’s short half-life makes it a compelling candidate for an oral drug delivery treatment for the main purpose of allowing simple daily, or multiple-times daily, administrations within or outside the hospital setting. Compared to injectable or intravenous treatments, oral therapy is the preferred drug delivery method of patients. Preliminary laboratory studies are encouraging and support the potential of developing an oral formulation, but there are no assurances made or implied that Cellceutix will be successful in completing development of an oral formulation. Toxicology studies for the oral formulation of Kevetrin began January 2017.

open-label Phase 2 Proof-of-Concept (P-o-C) trial of Brilacidin for the treatment of ulcerative proctitis (UP)/ ulcerative proctosigmoiditis (UPS), two types of Inflammatory Bowel Diseases (IBD).

The company has 4 ongoing ph 2 trials that are all targeted for completion relatively soon. (2017)





In Reply to 'scottsmith'
Kevetrin is a 1b trial, no? Maybe I'm wrong about that. If K is a 1b trial, I wouldn't consider that a mid phase trial. Personally, I wouldn't consider UP a mid phase trial either. A 17 person, 2a PoC trial doesn't meet that definition in my opinion.

I think we all care about the science. But the science is actually only one of multiple elements that determines a successful investment. Matter of fact, "the science" is the least controllable element to a bio investment. Financial, management, public relations, employees, trial design...can all be controlled more than "the science". Food for thought.